CP
VRCA icon

Caligan Partners’s Verrica Pharmaceuticals VRCA Stock Holding History

Caligan Partners’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.65M Hold
923,910
– – 0.27% 25
2026
Q1 		$4.89M Hold
923,910
– – 0.33% 23
2025
Q4 		$7.68M Hold
923,910
– – 0.63% 21
2025
Q3 		$3.98M Sell
923,910
-2
-0% -$12 0.52% 16
2025
Q2 		$4.9M Buy
923,912
+24,617
+3% +$132K 0.94% 15
2025
Q1 		$3.98M Buy
899,295
+156,326
+21% +$1.01M 0.83% 14
2024
Q4 		$5.2M Buy
+742,969
New +$8.17M 1.32% 13
2023
Q4 		– Sell
-25,959
Closed -$1.01M – 12
2023
Q3 		$1.01M Buy
+25,959
New +$1.32M 0.46% 10

Other funds holding VRCA

CC
Cannell Capital Alta, Wyoming $149M AUM 39.81% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Mariner
Mariner Overland Park, Kansas $95.2B AUM 32.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Caligan Partners's VRCA Position: Q2 2026 in Review

Caligan Partners held its Verrica Pharmaceuticals (VRCA) position steady in Q2 2026 at 923,910 shares worth $5.65M. The position accounts for 0.27% of the portfolio, ranked #25.

Caligan Partners first reported a position in VRCA in Q3 2023 and has held it in 8 quarters since. The position peaked at $7.68M in Q4 2025. 43 funds tracked by Wall St. Rank hold VRCA as of Q2 2026.

  • Caligan Partners held 923,910 shares of Verrica Pharmaceuticals worth $5.65M as of Q2 2026.
  • Caligan Partners left its Verrica Pharmaceuticals share count unchanged in Q2 2026.
  • Verrica Pharmaceuticals made up 0.27% of Caligan Partners's portfolio in Q2 2026, its #25 holding.
  • Caligan Partners first reported a position in Verrica Pharmaceuticals in Q3 2023 and has held it in 8 quarters since.
  • Caligan Partners's Verrica Pharmaceuticals position peaked at $7.68M in Q4 2025.
  • 43 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q2 2026.

Based on Caligan Partners's 13F filing for Q2 2026, filed 14 Aug 2026.